Streetbeat News

Products Services

TSLA

Mexican sculptor Chavis Marmol recently demonstrated his critique of Tesla and its CEO Elon Musk by dropping a nine-ton stone inspired by the Olmec civilization onto a Tesla Model 3. The event, aimed to 'troll Elon Musk,' took place in Mexico City and was supported by an anonymous donor and the artistic director of boutique hotel Colima 71. This act of protest comes as Tesla prepares to start construction on a new gigafactory in Mexico, highlighting cultural and societal critiques.

Portfolio Pulse from Chris Katje

March 26, 2024 | 8:17 pm

DRS

Leonardo DRS, Inc. (NASDAQ:DRS) has introduced a new Mounted Form Factor Mission System to support the U.S. Army's CMOSS modernization initiative. This system, compliant with the Army's C4ISR/Electronic Warfare Modular Open Suite of Standards (CMOSS), is designed to enhance flexibility and capabilities in mission command and other warfighting areas. It represents a significant step in network modernization, offering an open architecture platform that avoids vendor lock and proprietary IP issues, thereby facilitating continuous fielding of future technology. This development underscores Leonardo DRS's commitment to supporting the Army's modernization goals and its role as a leading provider of mission-critical tactical computing solutions.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 8:17 pm

RCKT

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) announced the appointment of Aaron Ondrey as Chief Financial Officer and made additional key appointments within its leadership team to expand capabilities across the company. These appointments are part of Rocket's preparation for its transition to a commercial stage and the continued development of its genetic therapy pipeline for rare disorders. Aaron Ondrey brings over 20 years of experience in financial management and strategic planning, having previously served as CFO of Mirati Therapeutics and held senior positions at Arena Pharmaceuticals, Alexion Pharmaceuticals, and Regeneron Pharmaceuticals. Other appointments include Kinnari Patel as President and COO, Jonathan Schwartz as Chief Medical & Gene Therapy Officer, Mark White as General Manager of Commercial Affairs, and Martin Wilson as General Counsel & Chief Corporate Officer.

Portfolio Pulse from Happy Mohamed

March 26, 2024 | 8:14 pm

SNDX

Syndax Pharmaceuticals has announced that the FDA has granted priority review to its New Drug Application (NDA) for Revumenib, aimed at treating relapsed/refractory KMT2Ar acute leukemia. The Prescription Drug User Fee Act (PDUFA) action date is set for September 26, 2024. The NDA is being reviewed under the FDA's Real-Time Oncology Review (RTOR) program.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 8:09 pm

AKLI

Akili has received a notice of allowance for its U.S. patent application 17/890,478, titled "Cognitive Platform for Deriving Effort Metric for Optimizing Cognitive Treatment (Using Data Computed with Artificial Neural Network or Deep Learning Techniques)". This development marks a significant step forward in the use of AI and deep learning in cognitive treatment optimization.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 7:58 pm

MDXXF

NUMIF

OPTHF

PharmAla Biotech (MDXXF) and Numinus Wellness (NUMIF) have entered into a sales agreement for MDMA supply for clinical trials in Canada. Similarly, Optimi Health (OPTHF) has partnered with Tel Aviv University for MDMA research on addiction. These deals mark significant advancements in MDMA-assisted psychotherapy and addiction research, with potential impacts on mental health treatment practices.

Portfolio Pulse from Lara Goldstein

March 26, 2024 | 7:35 pm

SHIBUSD

Shiba Inu (CRYPTO: SHIB) has seen a significant increase in daily transactions, whale activities, and total value locked, indicating a resurgence in interest and activity. The token's transactions surged to 412,270, a 516% increase, and whale transaction volume rose by 220.6% to $141.7 million. Additionally, Shiba Inu's total value locked reached a new all-time high of $3.77 million. This positive momentum is supported by its listing on Bitcoin.com.au and its popularity in Europe. The meme coin sector is entering a super cycle phase, highlighting the importance of strategic cryptocurrency exchange choices.

Portfolio Pulse from Khyathi Dalal

March 26, 2024 | 7:32 pm

CGC

Canopy Growth Corporation (NASDAQ:CGC) anticipates significant growth in the German cannabis market following its partial legalization, projecting an increase from under $500 million to over $2.5 billion in the next two years. CEO David Klein highlighted the potential for revenue growth, particularly through the medical channel. The company aims to expand its position as a top-three cannabis brand in Germany, capitalizing on the new legislation to boost profitability.

Portfolio Pulse from Erica Kollmann

March 26, 2024 | 7:30 pm

AMD

INTC

MU

NVDA

Micron Technology Inc (NASDAQ:MU) shares rose after Mizuho reiterated a Buy rating and increased its price target from $124 to $130, citing Micron's strong position in the AI and memory technology market. Analyst Vijay Rakesh highlighted Micron's potential in the HBM market, expected to grow significantly by 2026, and noted Micron's strategic moves, including capacity expansion and pricing strategies, as positive indicators for future gains. Rakesh also mentioned sustained traction at Nvidia Corp (NASDAQ:NVDA) and other companies like AMD (NASDAQ:AMD) and Intel Corp (NASDAQ:INTC) ramping up AI accelerators.

Portfolio Pulse from Anusuya Lahiri

March 26, 2024 | 7:25 pm

ARGX

Analyst ratings for argenx (NASDAQ:ARGX) have varied over the last quarter, with a recent shift towards more neutral positions. The average 12-month price target has increased to $465.1, up 3.64% from the previous target. Analyst actions include both upgrades and downgrades, reflecting changes in market conditions and company performance. Argenx, a Dutch company focusing on rare autoimmune diseases, has shown significant revenue growth but struggles with profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 7:01 pm